Bristol-Myers Squibb (NYSE:BMY) recently gained European Commission approval for Breyanzi, broadening treatment options for ...
Princeton: Bristol Myers Squibb has announced that the European Commission (EC) has granted approval to Breyanzi ...
1d
EC approves BMY's Breyanzi for relapsed or refractory FL, based on Phase 2 study showing high response rates & sustained ...
Squibb announced that the European Commission has granted approval to Breyanzi, a CD19-directed chimeric antigen receptor T ...
Bristol Myers Squibb has won European Commission expanded approval of its CAR-T cell therapy Breyanzi in the blood cancer lymphoma.
Bristol-Myers Squibb acquires 2seventy bio for $286M, marking the end of a once-promising biotech. Check out if this is a ...
The EC approved the CAR T-cell therapy based on data from a Phase II study showing a 94 percent complete response rate.
PRINCETON, N.J. - The European Commission has approved Breyanzi, a treatment developed by Bristol Myers Squibb (NYSE:BMY), a pharmaceutical giant with $48.3 billion in revenue and an impressive 75 ...
Investing.com -- The European Commission has granted Bristol Myers (NYSE: BMY) Squibb, the biopharmaceutical company based in ...
Bristol Myers Squibb buys 2seventy bio for $286 million, strengthening its cancer portfolio with Abecma CAR-T therapy for ...
Bristol-Myers Squibb recently declared a quarterly dividend ... Operational success was complemented by several drug approvals, including Breyanzi for lymphoma and Opdivo for esophageal cancer.
Bristol Myers Squibb has won European Commission expanded approval of its CAR-T cell therapy Breyanzi in the blood cancer lymphoma. The Princeton, N.J., biopharmaceutical company on Friday said ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback